Society and culture
Legal status
NovoSeven was approved for use in the United States in March 1999, and indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX. It was approved in October 2006, and indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.NovoSevenRT was approved for use in the United States in May 2008, as a room temperature stable formulation. In January 2010, the label was updated to include a black box warning on serious thrombotic adverse events associated with the use of NovoSeven RT outside labeled indications.In April 2020, coagulation factor VIIa (recombinant)-jncw (Sevenfact) was approved for use in the United States.On 19 May 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cevenfacta, intended for the treatment of bleeding episodes. The applicant for this medicinal product is Laboratoire français du Fractionnement et des Biotechnologies (LFB). The active substance of Cevenfacta is eptacog beta (activated), a blood coagulation factor (ATC code: B02BD08). Eptacog beta is almost identical to, and functions like, coagulation factor VII. It activates factor X, which starts the clotting process and thereby provides control of the bleeding.
Amlodipine/benazepril, sold under the brand name Lotrel among others, is a medication used to treat high blood pressure. It is a combination of amlodipine, a calcium channel blocker and benazepril, an angiotensin converting enzyme inhibitor. It may be used if a single agent is not sufficient. It is taken by mouth.Common side effects include cough, dizziness, and swelling. Serious side effects may include angioedema, myocardial infarction, high blood potassium, liver problems, and low blood pressure. Use in pregnancy is not recommended. Amlodipine works by increasing the size of arteries while benazepril works by decreasing renin-angiotensin-aldosterone system activity.The combination was approved for medical use in the United States in 1995. It is available as a generic medication. In 2019, it was the 213th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Medical uses
It is used to treat high blood pressure. It is not a first line treatment. References
External links
"Amlodipine mixture with Benazepril". Drug Information Portal. U.S. National Library of Medicine.